| SETD7 |
| LOCUS ID | 80854 | |||||||||||||
| GENE_SYMBOL | SETD7 | |||||||||||||
| GENE NAME | SET domain containing (lysine methyltransferase) 7 | |||||||||||||
| SYNONYMNS | KMT7, SET7, SET9, SET7/9 | |||||||||||||
| CHROMOSOME | 4 | |||||||||||||
| HOMOLOGENE ID | 12741 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| NA |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. SET7/9 gene silencing with siRNAs significantly attenuated TGF- beta 1-induced ECM gene expression. Furthermore, a TGF-beta 1 antibody not only blocked HG-induced ECM gene expression but also reversed HG-induced changes in promoter H3Kme levels and SET7/9 occupancy. Taken together, these show the functional role of epigenetic chromatin histone H3Kme in TGF-beta1-mediated ECM gene expression in mesangial cells under normal and HG conditions. Pharmacologic and other therapies that reverse these modifications could have potential renoprotective effects for diabetic nephropathy. | 20930066 |
| Cardiovascular | 1. Within this context, SET domain-containing (lysine methyltransferase) 7 (SET7, also called KMT7, SETD7, SET9) is of increasing significance due to its diverse roles in biological functions and diseases, such as diabetes, cancers, alopecia areata, atherosclerotic vascular disease, HIV, and HCV. | 26390175 |